Ravindra Gujar

Ravindra Gujar has a wealth of experience in the scientific field. Ravindra began their career in 2011 as a Doctoral Researcher at JNU-CSIR Institute of Microbial Technology, IMTECH, where they worked on "Dendritic cell antitumor activity is suppressed by c-Src via T cell immunoglobulin and mucin protein-3 (TIM-3) receptor". Ravindra also worked as an MSc Research at Madurai Kamaraj University during the same year, where they worked on "Expression and immunological characterization of Cardamom mosaic virus coat protein displaying HIV gp41 epitopes". In 2016, they moved to La Jolla Institute for Immunology as a Postdoctoral Researcher. In 2020, they became a Postdoctoral Scientist at Nationwide Children's Hospital. In 2021, they were hired as a Scientist at OncoSec Immunotherapy. Finally, in 2022, they became a Senior Scientist at Onchilles Pharma.

Ravindra Gujar has a well-rounded educational background. Ravindra obtained a B.Sc in Biotechnology from Jai Narain Vyas University between 2006 and 2009, followed by an M.Sc in Biotechnology from Madurai Kamaraj University between 2009 and 2011. Ravindra then went on to pursue a Doctor of Philosophy - PhD in Innate and Tumor Immunobiology from Jawaharlal Nehru University from 2011 to 2017.